Abstract: A detergent pack comprising a packaging container containing water-soluble unit-dose detergent products, wherein the container comprising a metallic layer at least partially encasing the products helps to reduce the formation of ammonia in the container. Each of the products comprises a detergent composition, which comprises more than 2.5 grams-active of malodour-generating aminocarboxylic complexing agent.

Abstract: Provided are a method of producing a beverage and a method of improving a flavor of a beverage by each of which the imparting of an undesirable aroma is suppressed. The method of producing a beverage according to one embodiment of the present invention is a method of producing a beverage using a raw material liquid, including adding hops that have been subjected to acid treatment to the raw material liquid. The method of improving a flavor of a beverage according to one embodiment of the present invention is a method of improving a flavor of a beverage to be produced using a raw material liquid, including adding hops that have been subjected to acid treatment to the raw material liquid, to thereby improve the flavor of the beverage.

Abstract: The invention relates to a bioreactor including: a light source (200); a light sensor (300) facing said light source; a vat (100) that is placed between the light source (200) and the light sensor (300), said vat being intended to receive a culture medium comprising a cellular culture of photosynthetic microorganisms; a controller (400) connected to the light sensor (300) in order to control the vat (100) to obtain a chosen cellular-culture concentration (xi) in the culture medium during a working period, said light source (200) being capable of emitting incident light (L) of an input light intensity (Iin) in the direction of the vat (100), and the light sensor (300) being capable of measuring an output light intensity (Iout) and of transmitting data relating to this intensity (Iout) to the controller for the control of the vat; and a system (500) for controlling the light source (200), this system being arranged to adjust, during a period shorter than or equal to said working period, the input light intensit

Abstract: An algal growth system can include a frame and a flexible sheet material that can have a substantially vertical orientation, where the flexible sheet material can be configured to facilitate the growth and attachment of algae, where the flexible sheet material can be supported by the frame. The algal growth system can include a first drive shaft, where the first drive shaft can be coupled with the frame, where the first drive shaft can support and actuate the flexible sheet material, a gear system, where the gear system can be coupled with the first drive shaft, a first roller, where the first roller can be coupled with the frame and can be configured to guide the flexible sheet material, and a drive motor, where the drive motor can be coupled with the gear system, where the drive motor can actuate the gear system and the at least one drive shaft such that the flexible sheet material can be actuated.

Abstract: The present invention relates in a first aspect to a plug flow tubular bioreactor having an integral or multi-part tube adapted for cultivation, and, optionally, infection, viral transduction, or transfection of eukaryotic cells. In a further aspect, the present invention relates to a plug flow tubular bioreactor system comprising the plug flow tubular bioreactor according to the present invention. Further, the present invention relates to a method for preparing virus particles, vectors, cells or other molecules including toxic molecules using the plug flow tubular bioreactor or the system according to the present invention. Finally, the present invention relates to the use of a plug flow tubular bioreactor for the preparation of virus particles, vectors including viral vectors, cells including modified cells or other molecules including toxic molecules.

Abstract: The invention relates to a device for hydrating with a liquid sample, the device comprising a container (4) for receiving at least one liquid sample, and a lid (5) possessing a bottom face (51) having at least one hydrating support (3) fastened thereto to present an absorption face (31) for absorbing a liquid sample. According to the invention, the container (4) presents, by means of at least one well (6), a calibrated volume for receiving a liquid sample, the at least said well presenting a hydrating calibrated open section for hydrating a hydrating support (3) defined by the top edge (8) of at least said well (6), the hydrating calibrated open section possessing an area that is less than the area of the absorption face of the hydrating support (3) in order to control the absorption by capillarity of the liquid sample by the hydrating support.

Abstract: The invention generally relates to a microfluidic platforms or “chips” for testing and understanding cancer, and, more specifically, for understanding the factors that contribute to cancer invading tissues and causing metastases. Tumor cells are grown on microfluidic devices with other non-cancerous tissues under conditions that simulate tumor invasion. The interaction with immune cells can be tested to inhibit this activity by linking a cancer chip to a lymph chip.

Abstract: A multi-layered microfluidic system featuring tissue chambers for cells in a first layer and a plurality of medium channels for culture medium in a second layer. The tissue chambers fluidly connect to the medium channels such that media flows from the medium channels to the tissue chambers, forming large-scale perfused capillary networks. The capillary networks can undergo angiogenesis and vertical anastomosis. The multi-layered configuration of the system of the present invention allows for flexibility in design.

Abstract: The disclosure relates to a bioreactor comprising at least one sheet of polymer material formed from a composition comprising: A. a copolymer of ethylene and at least one ?-olefin; and B. between 25 and 300 ppm by weight of ?-tocopherol relative to the component A.

Abstract: Provided is a cell treatment apparatus including a treatment chamber that is configured to secure a space for arranging therein a plurality of containers for use in treatment of cells in an inner space maintained in aseptic conditions, a gripping mechanism that is arranged in the treatment chamber and is configured to grip the plurality of containers arranged in the space, wherein the plurality of containers are capable of being arranged in the space so as to have their positions matched with predetermined positions of the plurality of containers so that the gripping mechanism can grip a container to be selected based on a command from among the plurality of containers.

Abstract: A device for centering of petri dishes, where the petri dishes include a bottom container with a lateral surface and a lid with a lid diameter, including an elevator with an elevator axis and an elevator drive, and the conveyor includes concentrically along the elevator axis a frustoconical through-hole tapering downwards, and the elevator drive is built to move a substantially flat plate from a neutral position downwards into a first position, which is reached as soon as the petri dish rests with its weight on the inner surface of the through-hole, and the elevator drive is built to rotate the plate during a movement of the plate from the neutral position into the first position.

Abstract: This large-scale cell culture system is for performing large-scale culture of cells by performing, in a closed system, subculture and transfer of spheroids and a culture medium by use of a vessel having a syringe structure, wherein the vessel comprises a front flange and a back flange which have a same circular outer shape and which are provided integrally with both ends of an outer cylinder part of the vessel, and the vessel allows rotary culture, utilizing the front flange and the back flange in a state where a head of the vessel is closed by a detachable cap and a space, in the vessel, closed by a gasket of a plunger is filled with a cell liquid obtained by suspending cells in a culture medium.

Abstract: Transfer of genetic and other materials to cells is conducted in a hands-free, automated and continuous process that includes flowing the cells between electroporation electrodes to facilitate delivery of a payload into the cells, while acoustophoretically focusing the cells. Also described is a control method for the acoustophoretic focusing of cells that includes detecting locations of cells flowing through a channel, such as with an image analytics system, and modulating a drive signal to an acoustic transducer to change the locations of the cells flowing in the channel. Finally, an electroporation driver module is described that uses a digital to analog converter for generating an electroporation waveform and an amplifier for amplifying the electroporation waveform for application to electroporation electrodes.

Abstract: The present invention relates to an apparatus and a method that can accelerate reproduction of odor from an air-conditioner by segmenting microorganisms, a temperature/humidity condition and nutrients for metabolism of the microorganisms as conditions for reproducing the odor from the air-conditioner and setting the segmented microorganisms, a temperature/humidity condition and nutrients for metabolism of the microorganisms according to an accelerated condition thereof.

Abstract: Provided herein are synthetic, three-dimensional (3D) bioprinted tissue constructs comprising porcine cells and methods of producing and using the same. The synthetic 3D bioprinted tissue constructs are fabricated by bioprinting spheroids comprising porcine cells, including genetically engineered cells, on a microneedle mold and fusing the spheroids to form an engineered tissue construct. Also provided are methods of using scaffold-free 3D bioprinted tissue constructs for applications related to drug screening and toxicity screening.

Abstract: Disclosed is a method for manufacturing a composite nanofiber support and a fish collagen/synthetic polymer nanofiber support manufactured by the method, wherein the method comprises: a first step for dissolving a synthetic polymer in an organic solvent; a second step for dissolving a fish collagen in water to prepare an aqueous fish collagen solution; a third step for adding the aqueous fish collagen solution prepared in the second step to the synthetic polymer solution prepared in the first step, followed by mixing; and a fourth step for electrospinning the mixture solution prepared in the third step to manufacture a nanofiber support.

Abstract: Embodiments are described that relate to methods and systems for growing cells in a hollow fiber bioreactor. In embodiments, the cells may be exposed to a number of growth factors including a combination of recombinant growth factors. In other embodiments, the cells may be grown in co-culture with other cells, e.g., hMSC's. In embodiments, the cells may include CD34+cells.

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making a structure including nanotubes, a structure including nanotubes, methods of delivering a fluid to a cell, methods of removing a fluid to a cell, methods of accessing intracellular space, and the like.

Abstract: The present invention is directed to systems and methods of processing aspirated adipose tissue for the isolation of stromal vascular fraction derived stem cells.

Abstract: Methods for improving the functionality and/or fertility of sperm, for example, by enhancing motility and/or extending the lifespan of sperm by subjecting the isolated sperm to a starvation protocol and/or ionophore are provided. Such methods may be used in, for example, artificial insemination to reduce the number of sperm needed for insemination and to improve conception rates.

Abstract: Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 ?m to about 8 ?m in size or about 4 ?m to about 6 ?m, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.

Abstract: Compositions and methods for producing major ocular cell types, including retinal ganglion cells, photoreceptors, retinal pigmented epithelium and corneal endothelial cells, from human pluripotent stem cells under defined culture conditions are provided.

Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and ad-mixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Abstract: The present disclosure relates to molecular biology, cell biology and immunology. Specifically, the present disclosure provides compositions and methods for modulating an isolated population of T lymphocytes to improve the therapeutic potential thereof.

Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

Abstract: The invention provides a T cell wherein one or more therapeutic transgenes is integrated at a within the genome of the cell such that expression of the transgene is under control of an endogenous promoter of the T cell. The invention additional provides methods of making and using such cells to treat a subject with T cell therapy. The invention also provides a T cell wherein a recombinant nucleic acid sequence encoding a chimeric antigen receptor (CAR) is integrated at a first site within the genome of the cell such that the CAR is expressed by the cell at the surface of the cell, and wherein integration of the nucleic acid encoding the CAR at the first site reduces or prevents expression of a functional T cell receptor (TCR) complex at the surface of the cell. The invention additional provides methods of making and using such cells to treat a subject with CAR therapy.

Abstract: The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.

Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

Abstract: Processes and compositions are provided for performing magnetibuoyant separations of different biomolecules (e.g., cells, organelles, etc.) in a biological sample, as well as compositions and kits for performing such methods. Compositions containing the separated biomolecules, and methods for using the same for in-vitro and in-vivo biomedical applications, are also provided. The magnetibuoyant methods of the invention employ targeted magnetic particles, preferably targeted nanomagnetic particles, and targeted buoyant particles such as buoyant microparticles and microbubbles. Among the benefits of the invention is the ability to combine targeted magnetic particles with differentially targeted buoyant particles to achieve separation of two or more specifically cell targeted populations during the same work flow.

Abstract: Described herein are methods and compositions relating to expanding, enriching, and/or maintaining a population of hematopoietic stem cells ex vivo. In some embodiments, the methods and compositions can relate to a combination of two or more agents, e.g.

Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE).

Abstract: Tissue processing devices are provided. The tissue processing devices can be used to process and transport tissue in a closed and continuous environment. The devices can be used for adipose tissue transfer, including autologous fat grafting.

Abstract: The present invention relates to compositions and methods for generating adult cells from pluripotent stem cells. The invention also relates to methods of treating disease using adult cells derived from pluripotent stem cells. The resulting adult cells are used for drug testing, drug screening, and regeneration therapy to treat heart diseases and neurodegenerative diseases.

Abstract: The present disclosure provides an apparatus for harvesting stem cells from fat tissue. The apparatus may include a first transducer coupled to a first end of an resonant horn to form an ultrasonic resonator. The resonant horn may include an elongated body having a plurality of through-holes configured to accommodate a plurality of specimen containers that are positioned substantially perpendicular to the elongated body. The apparatus may also include a wave generator coupled to the first transducer to generate an ultrasonic wave, wherein the elongated body has a length that is multiples of the half-wavelength of the ultrasonic wave.

Abstract: There is described an isolated 3-dimensional liver spheroid wherein said spheroid has: increased ATP content as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; the same or increased activity of cytochrome P450 1A1 and cytochrome P450 1B1 as compared to a 3-dimensional liver spheroid cultured in Complete William's E medium alone; and increased albumin secretion as compared to a 3-dimensional liver spheroid cultured in William's E medium alone.

Abstract: The invention relates to a method of preparing pancreatic islet-like cell structures characterized by a unique combination of morphological and functional features which make them particularly suitable for use in both clinical and drug screening application, as well as to the pancreatic islet-like cell structures obtained therefrom.

Abstract: Disclosed herein are methods for generating augmented SC-? cells, and isolated populations of augmented SC-? cells for use in various applications, such as cell therapy.

Abstract: The present invention is a method in which stem cells for which a differentiation state is unknown or cells that are differentiation-induced from the stem cells are use as test cells, and a differentiation state of the test cells is evaluated based on an abundance of a predetermined indicator substance in a culture supernatant of the test cells. The indicator substance is at least one compound selected from a group that consists of ornithine, 2-aminoadipic acid, deoxycytidine, glutamic acid, tryptophan, asparagine, alanine, cystine, hypoxanthine, uridine, aspartic acid, arginine, 2-hydroxybutyric acid, 2-hydroxyisovaleric acid, 3-hydroxyisovaleric acid, urea, 4-hydroxybenzoic acid, 4-aminobenzoic acid, ribonic acid, kynurenine, crystathionine, threonic acid, pyruvic acid, putrescine, ascorbic acid, riboflavin, serine, cysteine, orotic acid, and citric acid.

Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.

Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.

Abstract: This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.

Abstract: Provided are an enzyme involved in a glycyrrhizin biosynthetic system, a gene of the enzyme and use thereof in order to stably and continuously provide a large amount of glycyrrhizin. Glucuronosyltransferase with an activity of further transferring glucuronic acid to the hydroxy group at the 2-position of glucuronic acid in an oleanane-type triterpenoid monoglucuronide is identified to provide the transferase, a gene for the transferase and use thereof.

Abstract: The invention provides methods and compositions for inducing necroptosis in target cells, including for example cancer cells. This invention provides compositions and methods for the controlled expression and formation of full length RDPK3 homodimers, truncated RTPK3 oligomers and/or full length RIPK3/RIPK1 heterodimers in target cells both in vitro and in vivo therapeutic and research applications.

Abstract: Provided is genus Komagataeibacter microorganism having enhanced cellulose productivity and yield, a method of producing cellulose using the same, and a method of producing the microorganism.

Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.

Abstract: The disclosure features methods for treating or ameliorating at least one symptom of a subject having or being prone to a muscle weakness disease, comprising administering to said subject a therapeutically effective amount of at least one recombinant polypeptide having alkaline phosphatase activity.

Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

Abstract: The invention provides a mutant enzyme having trans-sialidase activity (EC 3.2.1.18), characterized by an enhanced trans-sialidase:sialidase ratio when compared to its parent sialidase enzyme. Further the enzyme may be used in a method for trans-sialylating mono- and oligo-saccharides, including galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), malto-oligosaccharides (MOS), isomalto-oligosaccarides (IMO), lactulose, melibiose, maltose, glycosyl sucrose, lactosucrose and fucose. Trans-sialidated mono- and oligo-saccharides, produced with the mutant enzyme, are useful in preparing infant formula, a prebiotic nutritional supplement, and a food supplement.